NGM Biopharmaceuticals Inc (NGM Bio) operates as a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases and ophthalmic diseases. The company’s pipeline products include NGM707, NGM831, NGM438, NGM120, NGM621, MK-3655 and Aldafermin. Its NGM707 is a novel dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript and NGM831 is the potential to fight tumors by shifting myeloid cells from a suppressive state to a stimulatory state and promote anti-tumor activity. The company’s biologic platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
333 Oyster Point Blvd, South San Francisco, California, 94080-1978
Website
www.ngmbio.com
Telephone
1 650 2435555
No of Employees
138
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NGM (NASD)
Revenue (2022)
$4.4M
-92%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
12.5%
(2022 vs 2021)
Market Cap*
$128.5M
Net Profit Margin (2022)
XYZ
-996.5%
(2022 vs 2021)
* As of and is in US$
NGM Biopharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Product: |
| Oncology: |
| NGM707 -Advanced Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In February, the company announced its plans to be acquired by Atlas. |
| 2022 | Official Trials/Tests | In March, the company dosed the first patient in a Phase 1/1b clinical trial of NGM831 for the treatment of patients with advanced solid tumors. |
| 2022 | Others | In February, the company announced U.S. Food and Drug Administration (FDA) granted Fast Track designation to NGM621. |
Competitor Comparison
| Key Parameters | NGM Biopharmaceuticals Inc | AbbVie Inc | AstraZeneca Plc | Inventiva SA | 89bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | France | United States of America |
| City | South San Francisco | North Chicago | Cambridge | Daix | San Francisco |
| State/Province | California | Illinois | England | Bourgogne | California |
| No. of Employees | 138 | 50,000 | 89,900 | 113 | 70 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William J. Rieflin | Chairman | Executive Board | 2022 | 63 |
| David J. Woodhouse | Director; Chief Executive Officer | Executive Board | 2018 | 53 |
| Jin-Long Chen | Chief Scientific Officer; Director | Executive Board | 2008 | 60 |
| Siobhan Nolan Mangini | Chief Financial Officer | Senior Management | 2020 | 42 |
| Jean-Frederic Viret | Chief Financial Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward